



## Call for Abstracts 2024 Annual Conference on Vaccinology Research (ACVR) May 8-10, 2024

The National Foundation for Infectious Diseases (NFID) invites abstract submissions of original research in the field of vaccinology. Abstracts are peer-reviewed for quality of research, educational, and scientific content. Accepted abstracts will be scheduled as either poster or oral presentations based on quality and anticipated interest.

### How to Submit:

[All abstracts must be submitted electronically through the online conference submission site](https://bit.ly/2024ACVRAbstracts)

[\(https://bit.ly/2024ACVRAbstracts\)](https://bit.ly/2024ACVRAbstracts). Users will be required to create an account after which they may begin the submission process and return to saved proposals at any time up until the submission deadline. Abstracts submitted by email, fax, or mail will not be accepted. Incomplete abstracts will not be reviewed.

### Schedule:

December 2023	Call for Abstracts submission site opens
February 29, 2024	Call for Abstracts closes
March 2024	Notifications sent
May 8-10, 2024	2024 Annual Conference on Vaccinology Research (Online)

### Topics for Abstract Submission:

The submitting author must select the most appropriate topic from the list below. The ACVR Planning Committee reserves the right to change the assigned topic for accepted abstracts.

- Behavioral Science
- Combatting Antimicrobial Resistance
- Epidemiology and Burden of Diseases
- Implementation Challenges and Solutions
- Innovation in Immunization
- Vaccine Disparities and Health Equity
- Vaccine Policy and Regulatory Pathways
- Vaccine Research, Development, Production, and Delivery
- Vaccine Safety, Monitoring, and Evaluation
- Vaccines Against Emerging and Re-Emerging Infectious Diseases
- Vaccines for Special Populations (Maternal Immunization, Immunocompromised, and High-Risk Groups)

## Abstract Format:

All abstracts must be submitted in English and must reflect original work. Abstracts based on prior presentations with updated information and additional data generated and/or analyzed are permitted. Multiple submissions of the same abstract will automatically be rejected.

Abstracts must contain the following components:

- **Abstract Title:** (75 word limit) a concise title summarizing the content
- **Background:** (200 word limit) a concise statement of the issue under investigation or a hypothesis
- **Methods:** (225 word limit) the experimental methods used (including the statistical analyses employed)
- **Results and Conclusions:** (250 word limit) a summary of specific findings and results (statistical analyses used to support the conclusions should be included; concluding statements such as “the results will be discussed” or “to be completed” are not acceptable)
- **References:** Users are **required** to submit at least one (but no more than 10) literature reference/citation to support research/data (multiple references are encouraged). Use the conventional style for listing references as referred by the American Medical Association (AMA) Manual of Style: A Guide for Authors and Editors. Sample reference formats are available at: <https://jamanetwork.com/journals/jama/pages/instructions-for-authors#SecReferences>.
- **Author(s):** (limit of 10 authors) Submittals must include the First Author, Presenting Author (individual who will be presenting the research at the conference if accepted), and any Co-Authors of the work. Note that the full contact information will be requested for all authors. The system allows users to send an email to each of the authors for them to complete this information directly.

### Note:

It is the responsibility of the submitter to ensure that all submitted abstracts are correct. Any errors in spelling, grammar, or scientific fact in the abstract text may be used as typed by the submitter.

## Selection:

All abstract submissions will be reviewed by members of the ACVR Planning Committee for scientific merit and relevance to the field of vaccinology. Review considerations include: clearly stated hypothesis or issue; experimental and statistical methods used; specific findings (statements such as “the data will be presented” are unacceptable); and specific conclusions (statements such as “the results will be discussed” are unacceptable). Authors of accepted abstracts will be invited to present their work in a 10-minute oral presentation or as a poster presentation.

## Poster and Oral Presenter Information:

Detailed information for preparing oral or poster presentations will be provided upon abstract acceptance. Oral presentations will be allotted a maximum of 10 minutes followed by a question and answer session from the audience. Poster presentations will be displayed online for registered attendees to view.

## Registration and Attendance:

Although there is no fee to do so, all abstract presenters must register for the conference by **April 10, 2024**, or their abstract may be withdrawn from the program. Presenters who fail to upload their poster or are not present during their assigned oral presentation time may have future abstract submissions automatically disqualified from consideration.

## **Abstract Publication:**

All abstracts will be available on the event website for registered attendees. Select presentations may be included in future publications with author permission.

## **Awards:**

**Maurice R. Hilleman Early-Stage Career Investigator Award** (<https://www.nfid.org/award/maurice-r-hilleman-early-stage-career-investigator-award/>)

The Maurice R. Hilleman Early-Stage Career Investigator Award recognizes individuals in the early stages of their careers in any field of vaccinology, to support their research. Winner will be recognized during the conference.

### **To apply for award consideration, applicants must:**

1. At the time of submission, be currently enrolled, have recently completed training (e.g., internship, residency, fellowship, postdoctoral training, or similar educational program), or be within 4 years of having earned an advanced degree (master's or doctoral).
2. Submit an abstract under the "Poster Abstract Only" submission type. Finalists will present a poster at the 2024 conference. Following judging, the winner will be announced and will present a 10-minute summary of their research during the conference.
3. Acknowledge that award winners of the Maurice R. Hilleman Early-Stage Career Investigator Award will be included in mandatory reporting to Centers for Medicare & Medicaid Services (CMS). All publications under the award must explicitly state that the awardees' work has been performed as a Maurice R. Hilleman Early-Stage Career Investigator Award recipient. Acknowledgement must also be given to NFID and all sponsors supporting the award.